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, is an increase in extramedullary haematopoiesis (EMH) and neutrophilia, which was later shown to result in immune evasion and tumour vascularization. Classically, this occurs within the host macroenvironment and is associated with increased serum haematopoietic, colony-stimulating activity 2 and abnormal myeloid cell differentiation, which results in a bidirectional molecular crosstalk between tumour cells and myeloid progenitor cells. Originally, these abnormal myeloid cells were described as veto cells, null cells or as natural suppressor (NS) cells and they were later shown to inhibit lymphocyte numbers and cytotoxic T lymphocyte (CTL) induction and activity 3 . These cells lacked membrane markers for mature T cells, B cells and natural killer (NK) cells, as well as macrophages 4, 5 , resulting in the nomenclature of null cells. Initially, their phenotypic characterization was contentious, and it continues to be partially unresolved owing to investigatordependent phenotypic marker profiles and cellular heterogeneity 6 . Consistent with tumour heterogeneity 7 , there is a tumour-dependent variability in myeloid cell expansion that may be associated with the secretion of differing cytokines and chemokines. In recent years, the concept of myeloid-derived suppressor cells (MDSCs) was introduced to reflect the abnormal nature of myelopoiesis in cancer, which is the focus of this article.
Studies have revealed that circulating MDSC numbers correlate with a poor prognosis, tumour vasculogenesis, osteoporosis and tumour evasion of host immunity [8] [9] [10] . A direct relationship between tumour burden and MDSC frequency has been demonstrated in several mouse tumour models 11, 12 and clinical studies [8] [9] [10] , and an inverse correlation between MDSC and T cell frequency in the peripheral blood has also been found 12 . Although this may be model dependent and, potentially, tumour dependent, a direct relationship between tumour burden and MDSC frequency and numbers is generally accepted. In support of this observation, the resection of solid tumours has been shown to decrease MDSC frequency in the peripheral blood and to reverse T cell suppression 13, 14 . The increase in the frequency and numbers of MDSCs depends both on tumour burden 12, 15, 16 and on the tumour-secreted factors [17] [18] [19] that regulate myeloid progenitor cell survival and expansion. Antibody-mediated depletion of MDSCs also restores T cell frequency and function 20, 21 . Confirmation of these observations using transplantable tumours has been provided by a mouse mammary tumour virus (MMTV) Erbb2-transgenic mouse model of breast cancer 22 . In this model, there was a direct association between the spontaneous development of metastatic mammary tumours and MDSC expansion. Similar observations have been made clinically with solid tumours, including a direct relationship with tumour state, and indirectly with T cell dysfunction 10 .
History of suppressive myeloid cells
In the mid-1960s, NS cells in tumourbearing mice were reported to induce a leukaemoid reaction that was related to the duration of tumour growth and myeloid cell infiltration 23, 24 (FIG.1 (TIMELINE) ). These cells were not only associated with tumour growth, but were also a major component of inflammatory and haematopoietic processes 3 , including in neonatal or newborn spleens, adult bone marrow 3 and adult spleens following total body irradiation (TBI) 4 . Subsequent studies revealed an increase in the numbers of NS cells in lymphoid and some parenchymal organs during tumour growth 24, 25 and following Bacillus Calmette-Guérin (BCG) 26, 27 injection. The tumour-induced granulocytosis, associated lymphopenia 24 and loss of T cell function 25 suggested a potential effect on cancer outcome, as well as therapeutic potential, if NS cells were downregulated. This potential has been supported by studies demonstrating that decreasing the numbers of myeloid cells in tumour-bearing mice is therapeutic 13, 28 . In the late 1970s, it was documented that a leukaemoid reaction or reactions included cellular populations that could inhibit CTL induction 29 and activity 3 . These cells, owing to a lack of expression of conventional membrane markers for T cells, B cells, NK cells and macrophages, were also described as NS or null cells 5, 30 . Functionally, they inhibited T cell proliferative responses, antibody production and CTL induction. They also suppressed antitumour immune responses and promoted immune evasion.
Mouse myeloid suppressor cells. Initially, the phenotypic characterization of null cells or NS cells in mice was contentious owing to a lack of phenotypic markers, and they were defined on the basis of a suppressive function 3 . Subsequently, mouse studies identified the phenotype of these cells (BOX 1) using the expression of single membrane markers, including CD34 (REF. 31 ), glutathione reductase (GR1; also known as GSR) 32, 33 or CD11b (also known as integrin-αM) 34 . NS cells in tumour-bearing mice were also characterized as committed myeloid progenitor cells and quantified as cycling progenitor cells, or immature cells of monocyte-macrophage lineage using a soft agar colony-forming assay 35 . Natural suppressor activity was also reported to be mediated by multiple cell populations 6, 36 , including cells from the spleen or bone marrow 37 . Early studies suggested that the most potent cyclophosphamide (CTX)-induced suppressor cell population was derived from Abstract | Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.
cells with a granulocyte-monocyte lineage that expressed CD11b 6 . This was supported by an observed 600-fold increase in granulocyte-macrophage colony-forming cells in the blood of mice following CTX injection compared with untreated controls 35 . Cells with a natural suppressor phenotype and function were also identified at sites of intense haematopoiesis 38 and found to be increased in number by tumour secretion [38] [39] [40] or by exogenous administration of haematopoietic growth factors, including granulocyte-macrophage colony-stimulating factor (GM-CSF) 41 and granulocyte-CSF (G-CSF) 42 . Thus, not only does tumour growth increase myeloid suppressor cells, but their numbers are also increased by haematopoietic growth factor administration, which potentially affects therapeutic intervention. It should be noted that cells with this phenotype are observed in the bone marrow of naive mice, but in the absence of T cell suppressive activity. It has been suggested that, in addition to their expansion, these immature cells need to be activated in order to be immunosuppressive 43 , so that these cells are not MDSCs in naive mice.
Phenotypic heterogeneity 44, 45 , without a consensus regarding the cellular phenotype that induces T cell dysfunction, broadened the already diverse nomenclature to include immature myeloid cells (iMCs), myeloid suppressor cells (MSCs) and GR1 + myeloid cells 46, 47 . 53 . This contrasts with CD11b + Ly-6G + Ly-6C low cells that have a granulocyte-like morphology, express high levels of arginase 1 (ARG1), and are identified as granulocytic-MDSCs (G-MDSCs). These cells have a polymorphonuclear (PMN) morphology and, therefore, the term PMN-MDSC is used interchangeably with the term G-MDSC. In most tumour-bearing mice, the G-MDSC population consistently increases, whereas the Mo-MDSC frequency is significantly increased in a limited number of tumour models 53 . Further, even in mice with tumours that have substantial increases in Mo-MDSCs, the G-MDSC population is also increased. Thus, the G-MDSC subset is the predominant MDSC population in tumourbearing mice 53 . This subset distinction can also be clarified by CD11b and GR1 expression 54 . 17 or on the use of alternative phenotypic markers, including F4/80 (also known as EMR1; a marker for macrophages) or MHC II (major histocompatibility complex class II) expression markers, which are also used to identify tumour-associated macrophages (TAMs). TAMs are a cellular population that can be histologically confused with MDSCs, but that are defined as mature, differentiated macrophages 55 . Distinguishing MDSCs from macrophages and, to a lesser extent, ADAM10 , a disintegrin and metallopeptidase domain-containing protein 10; ATRA, all trans-retinoic acid; BV8, bombina variagata peptide 8 homologue; COX2, cyclooxygenase 2; CSF, colony-stimulating factor; DC, dendritic cell; FLT3L, FMS-like tyrosine kinase 3 ligand; G-CSF, granulocyte-CSF; GM-CSF, granulocytemacrophage-CSF; GVHD, graft-versus-host disease; HIF1α, hypoxia-inducible factor 1α; HLA-DR, human leukocyte antigen d-related; HNSCC, head and neck squamous cell carcinoma; iNOS, inducible nitric oxide synthase; LIN, lineage; M-CSF, macrophage-CSF; MDSC, myeloid-derived suppressor cell; MLR, mixed lymphocyte reaction: MYD88, myeloid differentiation primary response 88; NF-κB, nuclear factor-κB; NO, nitric oxide; NS, natural suppressor; PDE5, phosphodiesterase type 5; RCC, renal cell carcinoma; SCF, stem cell factor; SCLC, small-cell lung cancer; STAT3, signal transducer and activator of transcription 3; VEGFA, vascular endothelial growth factor A. Human MDSCs. In the mid-1990s, G-CSFor GM-CSF-induced stem cell mobilization for autologous peripheral blood stem cell transplantation, predominantly for the treatment of patients with breast cancer or lymphoma, was found to result in myeloid cells with T cell suppressive activity that were defined as suppressive CD14 + monocytes [63] [64] [65] (FIG.1 (TIMELINE) ). Indeed, studies of monocyte-associated suppressive activity revealed a direct relationship between the number of CD14 + cells and suppressor cell function in mobilized stem cell products 64 , as well as characteristics of cells with a monocyte lineage 66 . Subsequent studies of patients with breast cancer following stem cell transplantation revealed that T cell number and function inversely correlated with T cell suppressor activity and CD14 cell frequency in the peripheral blood posttransplantation 38, 64 and from patients with advanced disease 67 . This inhibitory cell was isolated from peripheral blood stem cell (PBSC) products and shown to be a CD14 + myeloid cell 68 constituting up to 40% of the cells in the apheresis product. Further, 10% or more of peripheral blood leukocytes following peripheral stem cell transplant (PSCT) 69 were shown to be CD14 + with T cell suppressive activity 65 .
In the late 1990s, human MDSCs were also described in patients with head and neck cancer on the basis of CD34 expression and T cell suppression in patients with GM-CSF-secreting cancers 38, 64, 70 CCR2, C-C chemokine receptor type 2; CXCR, C-X-C chemokine receptor; GR1, glutathione reductase; HLA-DR, human leukocyte antigen d-related; IL-4Rα, interleukin-4 receptor-α; LIN, lineage; Ly-6, lymphocyte antigen 6; M-CSFR, macrophage-colony-stimulating factor receptor; MHC, major histocompatibility complex; NA, not applicable; SCA1, stem cell antigen 1; VEGFR, vascular endothelial growth factor receptor.
Various phenotypic markers of mouse and human myeloid-derived suppressor cell (MDSC) subsets have been identified (see the table; + indicates expression and -indicates lack of expression). Their phenotypes have been controversial, and numerous phenotypes have been used to define MDSCs and their subsets. In some instances, the expression levels are identified as low or bright, a difference that may also be relevant to other markers. The cellular phenotypes can be divided into monocyte (Mo), granulocyte (G) and endothelial-committed MDSC subsets (see the table) . Circulating endothelial progenitor cells (EPCs) as an MDSC subset is not well established, and numerous markers have not been determined (ND). The term 'subset' recognizes that not all of the MDSCs or EPCs express the corresponding marker. Similarly, the term 'some models' documents that some but not all tumour models have been reported to express a marker. We note that the relationship between EPCs and MDSCs remains obscure and EPC is presented as a subset here to suggest a potential relationship. Reviews that discuss MDSC phenotypic markers include the following references for mouse 60, 81 and human 76, 84, 174, 190, 191 studies.
MDSCs were initially defined as HLA-DR 67, 75 . The expression of CD14 on MDSCs as a Mo-MDSC marker was initially controversial but has now become accepted. Nonetheless, CD14 expression is difficult to use as a lineage marker as PMNs also express low levels of this marker. Thus, differentiation between CD14 br versus CD14 low in the assessment of MDSCs is crucial. Human MDSCs have been further subdivided on the basis of maturity 76 , although the definition of these subsets has not yet reached a consensus. The identification of a precursor subset supports MDSC plasticity and their potential to differentiate into not only granulocytes, monocytes and DCs, but also osteoclasts and endothelial cells. Currently, additional phenotypic parameters are under investigation, including high CD66b (also known as CEACAM8) levels, low levels of CD62L (also known as L-selectin), low CD16 expression 76 , vascular endothelial growth factor receptor 1 (VEGFR1; also known as FLT1) expression 75 and S100A9 expression 77 . However, S100A9 is not expressed on the cell membrane and cannot be used to isolate cells.
Myeloid cell populations are the predominant population in the peripheral blood (both in number and function), in tumour infiltration and in supporting tumour growth and progression 78 . Although granulocytes are the first line of defence against tumour challenge, they also have a protumorigenic role, resulting in an immune paradox. The basis for this functional MDSC plasticity, which is observed in both mice and humans, is their capability to express different functional profiles in response to varying environmental signals, including cytokines, growth factors, acidosis, hypoxia, interstitial pressure and glucose levels. Hypoxia and hypoxia-inducible factor 1α (HIF1α) are partially responsible for the regulation of ARG1 and iNOS expression by mouse MDSCs and their differentiation. Similarly, the tumour-dependent profile of secreted cytokines also regulates MDSC differentiation, supporting the conversion between MDSC phenotypes, differentiation and activation. However, the exact combination and sequence of tumour-derived and microenvironmental factors that regulate MDSC mobilization, proliferation, abnormal differentiation and activation remain poorly understood. Consequently, current studies focus on mechanisms and molecules driving the pro-tumoural skewing and phenotypic heterogeneity of circulating and tumourinfiltrating MDSCs. Similar to mouse MDSCs, human MDSCs are haematopoietic progenitors that can differentiate into not only granulocytes and monocytes, but also endothelial cells and osteoclasts. Although specific growth factors drive MDSCs to differentiate, whether different MDSC profiles between tumours are due to tumour heterogeneity, or whether a consistent profile, which is based on tumour histiotype, exists is unstudied.
Mechanisms of myeloid cell and tumour cross-regulation. Haematopoietic abnormalities in tumour-bearing hosts, originally described as neutrophilia and characterized by the abundance of less mature cells 79 , have long been observed 1 . Mechanistically, this is associated with tumour secretion of cytokines and chemokines that induce myeloid cell proliferation, accumulation and tumour infiltration 18, 22, 80 . However, many of these accumulating cells are not mature cells, as originally described, but are instead progenitor cells with immunosuppressive activity and the ability to differentiate not only into granulocytes, histiocytes and DCs, but also into endothelial cell precursors and osteoclasts. Myeloid cells respond to a wide range of stimuli, most notability their molecular microenvironment and the heterogeneous milieu of tumour-secreted cytokines. The plasma cytokines and chemokines differ between tumour-bearing hosts (both in humans and in mice), resulting in tumour-dependent proliferation, sites of accumulation and infiltration. This has made it difficult to determine the crucial factors that result in MDSC activity in the tumour microenvironment. Further, not only do tumours secrete growth factors that induce myelopoiesis and chemokines that mobilize and marginate MDSCs, but they may also limit their maturation and differentiation, thereby contributing to their accumulation 81 . Thus, tumour necrosis factor (TNF) impairs MDSC maturation 82 by regulating the receptor for advanced glycation end products (RAGE; also known as MOK) and its ligands (S100A8 and S100A9) 83 . Additional, proinflammatory mediators, such as IL-1β, IL-6, leukotriene D4 (LTD4) and prostaglandin E2 (PGE2) that regulate MDSC accumulation and activation, may also affect MDSC differentiation, but remain to be assessed for these functions. The heterogeneity in the processes that regulate MDSC proliferation, accumulation and trafficking has been documented both in mouse models 53 and in the clinic 84 
. These processes include mobilization and proliferation (most notably as EMH), maturation, arrest,
Glossary
Extramedullary haematopoiesis (EMH). The proliferation of haematopoietic cells outside of the bone marrow in response to pathological processes, such as tumour growth, and can occur at different locations, such as the liver and spleen.
Host macroenvironment
Includes the systemic factors (growth factors, cells, tissues and organs) that can regulate tumour growth, progression and metastasis, including factors, such as age, menopausal status, body mass index and overall immune status.
Leukaemoid reaction
A peripheral blood phenotype resembling that of leukaemia, or indistinguishable from it, based on cellular morphological appearance; observed in some infectious diseases, inflammatory conditions and neoplasia.
Margination
A process that occurs during the early phases of inflammation; as a result of capillary dilation and slowing of the bloodstream, leukocytes occupy the periphery of the cross-sectional lumen and adhere to the endothelial cells that line the vessels.
Mobilization
The release of haematopoietic progenitor cells from the bone marrow into the peripheral blood.
Neutrophilia
An absolute or relative increase in the normal number of neutrophils and their precursors in the circulating blood that may be associated with acute infections, malignancy or following severe haemorrhage or neutropenia (compensatory neutrophilia).
Plasticity
The capacity of cells with the same genotype to vary in differentiation, in phenotype or in function in response to varying environmental conditions.
Tumour angiogenesis
The growth of blood vessels and capillary beds from existing vessels into a solid tumour.
Tumour microenvironment
The milieu surrounding tumours, including normal cells, blood vessels, soluble factors and molecules, that can influence and be influenced by tumour growth.
Tumour vasculogenesis
The formation of new capillaries and blood vessels by endothelial progenitor cells.
trafficking and margination, all of which contribute to organ and tumour accumulation. Indeed, MDSCs within tumours have been shown, using the 4T1 tumour model, to be derived from splenic and hepatic EMH before tumour infiltration 11 . Therefore, macroenvironmental changes, such as the types and extent of circulating cytokines and chemokines, have a crucial role in regulating infiltrating cells in the tumour microenvironment such that MDSC pathobiology is regulated by the macroenvironment via altered myelopoiesis and differentiation 56, 85, 86 in association with tumour-derived haematopoietic growth factors and chemokines.
Regulation of MDSCs
Regulation of MDSC proliferation. Building on our understanding of tumour progression and metastasis, tumoursecreted chemokines, growth factors and enzymes that contribute to myeloid cell expansion, differentiation and recruitment have also been suggested to regulate tumour progression and metastasis. The effect of MDSCs on tumour progression and metastasis is observed in vivo by downregulation of neutrophilia following tumour resection 13, 14, 28, 87 , intervention using antibodies to myeloid cells 18, 88 or growth factor inhibitors 20 . The increase in circulating myeloid cells in tumour-bearing hosts, originally termed reactive neutrophilia or emergency granulopoiesis, was associated with an increased frequency of iMCs. Improvements in biomarkers identified neutrophilia with an increase in circulating colony-forming unit in culture (CFU-c) and, recently, MDSCs. Mechanistic studies using tumour-conditioned media (TCM) in cultures of spleen 15 , bone marrow 56 and isolated myeloid or progenitor cell subsets 53, 89 have identified mediators and have resulted in MDSC survival, proliferation, differentiation and function, as well as T cell proliferation and DC function 90 and differentiation 33 . 57 . Indeed, studies using transplantable tumours linked tumour GM-CSF secretion to MDSC expansion 17, 40, 41, 94 : the knockdown of GM-CSF in tumour cell lines resulted in an altered MDSC number and subset distribution following tumour growth 17 . Consistent with such studies, and depending on the tumour studied, antibody neutralization or molecular inhibition of GM-CSF, GM-CSF receptor 15, 94, 95 , M-CSF 96, 97 , VEGFA 91,98 , S100A8 and S100A9 (REF. 81 ), G-CSF 18 or SCF 92 , has also been shown to inhibit MDSC accumulation and MDSC recruitment to the tumour microenvironment and to delay tumour development (TABLE 1) . In a mouse model of mammary cancer (BALBneuT mice, which develop ERBB2-driven mammary tumours), investigators reported a direct correlation between tumour progression and the numbers of immature GR1 + CD11b + CD131 + cells with immunosuppressive activity 91 . G-CSF, similarly to GM-CSF, can also facilitate G-MDSC accumulation, as well as regulate granulopoiesis and neutrophil mobilization 99 . Increased G-CSF levels have been shown to inhibit innate and adaptive immunity 100 and are aberrantly expressed by diverse human tumours 101 . G-CSF production also correlates with atypical MDSC-like responses in mouse tumour models 22, 80 ; however, the correlation between G-CSF and MDSC accumulation has generally focused on systemic MDSC responses 102 , with limited studies assessing the effect of G-CSF on Mo-MDSC versus G-MDSC subsets 11 . Although it remains unclear whether a specific growth factor is unique to a defined tumour histiotype, tumour secretion of growth factors regulates MDSC proliferation.
In vitro mechanistic studies to assess MDSC regulation have demonstrated that TCM, but not control media, can induce the proliferation of KIT + MDSC precursors 15 , resulting in a cell population that is predominantly GR1 + CD11b + (REF. 103 ). In one study, proliferation and differentiation of KIT + MDSC splenocytes was only observed with GM-CSF and not with recombinant VEGFA or SCF, and only minimally with IL-6 (REF. 15 ). However, an intermediate level of proliferation was observed with high concentrations of M-CSF. More importantly, addition of a neutralizing GM-CSF antibody to the TCM culture abrogated MDSC generation from KIT + precursors. Neutralizing antibodies to other cytokines, such as SCF, IL-6 and IL-1β, had no effect, suggesting that GM-CSF is both necessary and sufficient to generate functional, immunosuppressive MDSCs in vitro. Thus, GM-CSF was suggested to be the tumour-associated proliferative factor for MDSC differentiation and proliferation (that is, secreted by
Box 2 | Regulation of MDSCs
Since the first characterization of myeloid-derived suppressor cells (MDSCs), which were previously known as natural suppressor (NS) or null cells, they have been controversial. They are similar to monocytes and granulocytes, with common morphological and phenotypic features. However, MDSCs result from the expansion of myeloid precursor cells and are defined as immature myeloid cells (iMCs) with potent immune suppressive activity. They have an impaired ability to differentiate into mature myeloid cells, and accumulate in peripheral lymphoid and parenchymal organs. Despite phenotypic homogeneity, MDSCs do not exist in healthy hosts, at least in the absence of activation, and are only observed during chronic pathological conditions, such as infections, inflammation or cancer. Furthermore, the mechanisms responsible for MDSC expansion, trafficking, abnormal differentiation and function remain to be clarified. There are several mechanisms and mediators that regulate MDSCs and these can be patterned on the basis of the mobilization of haematopoietic progenitors, which are the 'normal' cellular population most similar to MDSCs (see the table).
Process or mechanism
Examples of mediators MDSC proliferation in the bone marrow and EMH ATRA and vitamin D ATRA, all trans-retinoic acid; CXCL, C-X-C motif chemokine; EMH, extramedullary haematopoiesis; G-CSF, granulocyte-colony-stimulating factor; GM-CSF, granulocyte-macrophage-colony-stimulating factor; LTD4, leukotriene D4; PGE2, prostanglandin E2; SCF, stem cell factor; TLR, Toll-like receptor; TNF, tumour necrosis factor; VEGFA, vascular endothelial growth factor A.
tumours, not by normal epithelial cells, resulting in immunosuppressive MDSCs from KIT + splenocytes) 15 . Recently, organ-dependent 16 and tumour-dependent 104 MDSC proliferation was shown to partly rely on tumour-derived microenvironmental and macroenvironmental growth factor levels, which vary in a tumour and in an anatomical manner 3, 12, 16, 95 . In one study, MDSC numbers in the spleen directly correlated with tumour G-CSF transcript levels, whereas MDSC numbers in the tumour directly correlated with splenic GM-CSF transcript levels, tumour volume and tumour cell numbers 14 . The observation of EMH in reticuloendothelial 6 and parenchymal tissues 3,24 is well established; however, its role in MDSC accumulation has been little studied 32, 105 .
Indeed, adult non-tumour-bearing mice have few splenic progenitor cells 33 ; however, when stressed, haematopoietic progenitor cells mobilize from the bone marrow, arrest, and accumulate in lymphoid and parenchymal organs 106 . Studies using 4T1 tumour-bearing mice revealed a splenic myeloid cell reservoir that primarily consists of CD11b + Ly-6G bright cells 11 . Circulating MDSCs arrest and accumulate in the splenic marginal zones and periarteriolar lymphatic sheaths, migrate to the red pulp and proliferate within the subcapsular red pulp. The GR1 dull subset of MDSCs was reported to have a higher proliferation rate in the bone marrow 107 , although both MDSC subsets proliferate in the spleen 11, 108 . Similarly, clinical and rodent therapeutic strategies (TABLE 1) to induce MDSC differentiation, such as the administration of all trans-retinoic acid (ATRA) 109, 110 or vitamin D 70, 111 , have also been shown to reduce MDSC number and/or function.
The pro-inflammatory proteins S100A8 and S100A9 can also support MDSC expansion and block myeloid precursor cell differentiation. S100A8 and S100A9 are highly expressed in the tumour microenvironment, potentially supporting MDSC recruitment 112 . Tumour secretion of VEGFA, G-CSF and GM-CSF (as discussed above) is also at least partially responsible for MDSC expansion 91 . However, other mechanisms are also involved, including matrix metalloproteinase 9 (MMP9) secretion and the associated remodelling of the extracellular matrix, promotion of angiogenesis and stimulation of VEGFA production 113 . COX2, cyclooxygenase 2; CSF1R, colony-stimulating factor 1 receptor; CXCR, CXC chemokine receptor; G-CSF, granulocyte-colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-MDSCs, granulocyte-MDSCs; IL-6R, interleukin-6 receptor; iMCs, immature myeloid cells; MDSC, myeloid-derived suppressor cell; Mo-MDSCs, monocyte-MDSCs; PDE5, phosphodiesterase type 5; PMN, polymorphonuclear; PPARγ, peroxisome proliferator-activated receptor-γ; PROK2, prokineticin 2; RCC, renal cell carcinoma; TAM, tumour-associated macrophage; TKI, tyrosine kinase inhibitor; VEGFA, vascular endothelial growth factor A.
Regulation of MDSC mobilization. The haematopoietic system cycles continually from a small population of pluripotent haematopoietic stem cells (HSCs) as part of a delicate balance between quiescence and proliferation in addition to self-renewal and differentiation. Quiescence and self-renewal are tightly regulated by both cell-intrinsic signals and environmental factors 114 . However, tumours subvert this niche-signal-mediated maintenance of HSC dormancy, leading to rapid HSC proliferation and to differentiation that results in a selective loss of lymphocytes but levels of myeloid lineage cells are maintained. In adults, under steadystate conditions, HSCs and progenitor cells are primarily found in the bone marrow, although low numbers circulate in the blood and traffic to haematopoietic and nonhaematopoietic organs 115 where they proliferate and differentiate as EMH 116 . Mobilization is the first step in myeloid progenitor trafficking to inflammatory sites. However, there has been little study of the mechanisms governing MDSC mobilization, their subsequent trafficking to sites of EMH and tumours, and the suppression of these processes (TABLE 1) . These processes include alterations in the adhesive interactions between myeloid progenitor cells and stromal cells during transmigration through the subendothelial basal lamina and the endothelial cell layer 117 . During steady-state haematopoiesis, GM-CSF and G-CSF not only regulate proliferation, but also (directly or indirectly) mobilize cells from the bone marrow and spleen 118 . In addition, growth factor administration or secretion from tumours results in myeloid hyperplasia, thereby increasing prosteroid and neutral protease secretion that also regulates mobilization, myeloid progenitor cell survival, and their distribution between marginal and circulating pools 119 . Because MDSCs include myeloid-committed haematopoietic progenitors and are probably fixed at an immature differentiation stage 120 , the mechanisms associated with their mobilization may be similar to those of haematopoietic progenitor cells.
Treatment of humans or mice with selective antagonists of CXCR4, CXCR4-blocking antibodies or CXCL12 expression 121 , results in a rapid (1-4 hours) mobilization of neutrophils, myeloid progenitors and MDSCs 57, 121 into the blood. This suggests that disrupting CXCR4 signalling can contribute to G-CSF-induced mobilization and granulopoiesis 89, 121 . G-CSF administration also induces protease secretion in the bone marrow microenvironment, contributing to cellular mobilization 122 . The rapid mobilization by chemokines (minutes to hours) compared with G-CSF (days) supports multiple mechanisms. Accumulating evidence suggests that CXCL12 has a key role in controlling myeloid cell mobilization and homeostasis 123 . Thus, mice deficient in CXCL12 or CXCR4 die perinatally with neutrophilia and fail to establish bone marrow myelopoiesis 124 . CXCL12 also functions as a retention signal, constraining CXCR4-expressing haematopoietic progenitor cells to the bone marrow. However, CXCL12 is subject to amino-and carboxyterminal proteolytic modification, reducing its chemotactic activity 125 .
Regulation of MDSC trafficking and arrest.
Chemokines have a role in leukocyte recruitment and arrest in the tumour microenvironment, as do members of the integrin and selectin adhesion molecule families 126 . Several chemokines 89, 112 attract myeloid cells to the tumour microenvironment 127 , and also stimulate the secretion of extracellular matrix-degrading enzymes 127 . However, myeloid cells also express integrins 128, 129 , providing another mechanism to regulate cellular trafficking in vascular microenvironments 130 . One of these integrins is α4β1, a receptor for vascular cell adhesion molecule (VCAM) and fibronectin, that selectively promotes the arrest of endothelial progenitor cells (EPCs) 131 and monocytes 130, 132 , to neovascular tissue. Human CD34 + and mouse LIN − SCA1
+ progenitor cells, as well as bone marrow-derived myeloid cells (CD14 + CD11b + ), adhere to tumour endothelium in vivo via integrin α4β1 (also known as VLA4). The blockade of α4β1 in tumourbearing mice suppresses myeloid progenitor cell tumour infiltration and reduces blood vessel density. Integrins also mediate progenitor cell arrest at sites of ischaemia 133 so that circulating EPC adhesion to endothelial monolayers requires integrin β2 expression.
Adoptive transfer studies 16, 57 with carboxyfluorescein succinimidyl ester (CFSE)-labelled MDSCs from tumour-bearing mice demonstrated that MDSCs rapidly transverse the pulmonary capillary networks and accumulate in the spleen 16 . By contrast, injection into naive mice results in MDSC arrest primarily in the lungs. Consistent with these findings, an analysis of MDSC proliferation by BrdU labelling revealed proliferation predominantly within the spleens of both naive and tumour-bearing mice 16 . MDSC accumulation is also a result of prolonged MDSC survival, decreased apoptosis and significantly increased proliferation and accumulation in the spleens, but not in the bone marrow, of tumour-bearing mice. Support for this observation was provided by Ki-67 staining, which revealed that MDSCs proliferated in the cords of the subcapsular red pulp, with GR1 + cells infiltrating throughout the red pulp and marginal zones 38 . In these studies using 4T1 tumourbearing mice, the spleen, but not the bone marrow, was shown to be the primary site of MDSC proliferation, and was also shown to provide a reservoir of Ly-6G + MDSCs that can rapidly demarginate and recirculate 16 . Further, this organ-specific proliferation is unique to tumours 134 , and the frequency of Mo-MDSC versus G-MDSC subsets differs between tumours and organs 16 so that, in 4T1 tumour-bearing mice, G-MDSCs have a significantly higher cellular frequency than Mo-MDSCs in the peripheral blood and spleen 53, 60, 95 . This higher frequency is also present in the liver, but not in the lungs. Most MDSC studies have focused on MDSCs within the peripheral blood, spleen or tumours; however, MDSCs also accumulate in the liver 12, 135 , including following adoptive transfer of splenic MDSCs 11 . Further, MDSC tumour infiltration is tumour-dependent and associated with a high frequency and absolute number of MDSCs infiltrating the spleen, liver, lungs and peripheral blood 16 .
Tumour progression and metastasis
The tumour regulation of MDSCs is bidirectional, and activated MDSCs secrete chemokines, cytokines and enzymes 136 that contribute to tumour cell invasion, proliferation, survival, adhesion and chemoattraction, resulting in a crosstalk that can affect tumour progression, invasion and metastasis 137 . Tumour progression and metastasis are multistage processes that are facilitated by MDSCs, as documented by inverse correlations between outcome parameters and myeloid cell infiltration of tumours and circulating MDSC frequency 10, 138 . The stages of tumour progression and metastasis and their regulation by MDSCs are shown in FIG. 2 . Studies in the late 1970s stimulated research into the pathobiology of metastasis, building on the studies by Paget 139 who developed the 'seed and soil' hypothesis (FIG.1 (TIMELINE) ). Since then, our understanding of the tumourpromoting role of chronic inflammation has greatly increased. Many of the key soluble and cellular mediators involved in this process have been identified, and promising studies in mice focused on the control of MDSC number and function have been carried out. The adoptive transfer of MDSCs has been shown to significantly promote tumour 113, 140 , and GR1 + cell depletion in tumour-bearing mice inhibits tumour growth, reduces metastasis and prolongs survival 20, 21, 141 . Some chemotherapeutic agents preferentially suppress MDSCs, including gemcitabine 141 , 5-fluorouracil 142 and docetaxel 143 . Numerous studies of tumourbearing mice, and a few clinical studies using therapeutics that target MDSCs or their function, have shown that MDSC reduction delays tumour initiation and progression in mice, and prolongs survival 110, 144, 145 (TABLE 1) .
Definitive proof that a clinical reversal in MDSC number or function can significantly delay tumour progression or growth remains to be established. However, it has recently been demonstrated that immune evasion limits cancer immunotherapies; and MDSC suppressive activity seems to be one of the more prevalent mechanisms to be present in cancer patients, providing an obstacle to immune-based intervention. It should be stressed that the mechanism of T cell suppression and the identification of the MDSC subsets that are crucial to immune subversion remain controversial. Thus, in contrast to results to date, adding interventional strategies that reverse MDSC immune suppressive activity supports adjuvant immunotherapy 110, 146 and slowing of tumour . MDSC diversity results in multiple roles during tumour progression, and future studies must define the mechanisms underlying their different functions with respect to tumour progression. Clearly, investigators should pursue other therapeutic strategies to regulate MDSCs on the basis of their multiple tumorigenic activities (FIG. 2) .
MDSC regulation of tumour invasion.
Tumour and myeloid cell secretion of enzymes facilitates invasion, and positive correlations have been reported between proteases, such as MMP9, and tumour malignancy 148 . MicroRNA-494 (miR-494) 89 and HIF1α 149,150 also have a role in regulating the non-immunological activity of MDSCs by enhancing their ability to infiltrate tumour tissue and, in the case of miR-494, to facilitate tumour invasion via the upregulation of MMPs 89 . Therefore, MDSCs, which secrete high levels of proteolytic enzymes, may facilitate invasion into the host stroma, but also intravasation through capillary basement membranes, resulting in increased numbers of circulating tumour cells. MDSCs promote tumour invasion by the secretion of MMPs 150 , which have an essential role in extracellular matrix degradation 113, 151 . Support for a role of MDSCs in tumour invasion was provided by studies that used a mammary carcinoma lacking the type II transforming growth factor-β (TGFβ) receptor 151 that resulted in an enhanced incidence of metastasis and an increased MDSC tumour infiltrate 152 . The enhanced invasion was MMP dependent; however, it was not clear whether the MMPs were secreted by MDSCs or by the carcinoma cells in response to MDSC stimulation 151 . Both cell populations are probably involved, as MDSCs derived from tumour-bearing hosts have increased MMP levels compared with 'MDSCs' from non-tumour-bearing hosts 151 , suggesting that some of the increased invasive ability may be from MDSC-derived MMP secretion.
MDSC regulation of tumour cell arrest and niche formation. Although metastasis is an inefficient process 153 , during which few tumour cells survive trafficking through the circulation, arrest and interactions with host immunity, survival is facilitated by the formation of heterotypic emboli secondary to tumour cell interactions with myeloid cells and platelets 154 . These emboli physically protect tumour cells from the host immunity, as well as larger emboli that more frequently arrest in the organ parenchyma. However, once tumour cells have extravasated, their growth is regulated by the cellular and growth factor milieu in the microenvironment 155 , which has been termed a metastatic niche 156 . These niches are partly controlled by macroenvironmental changes, including the number of circulating MDSCs and EPCs. Such niches have been suggested to function as chemoattractants 157 ; however, this may be irrelevant as tumour cells circulate and arrest on the basis of physical constraints and adhesion factor expression. Further, increases in MDSC and EPC numbers, at least in tumour-bearing mice, occur in numerous solid organs, including the spleen, lung and liver. Indeed, in rodent models, MDSC frequency is highest in the spleen; however, in mice this site is abnormal for metastatic formation by carcinomas. By contrast, MDSCs also occur at a high frequency in the lungs and liver, which are often metastatic sites. However, as reported by Hart et al. 155 , even when organ fragments are implanted ectopically, organ-specific milieu regulates tumour cell arrest and growth, suggesting that mechanisms in addition to myeloid cell expansion and angiogenesis are crucial, notably hormonal and organspecific growth factors 155 . Thus, metastasis is both selective and inefficient 158 , and only a few cells survive to form a micrometastasis, a process that is partially regulated by MDSCs and other myeloid cells.
MDSC regulation of vasculogenesis and angiogenesis.
Infiltrating and circulating MDSCs have also been suggested to have a role in tumour angiogenesis and vasculogenesis. Tumour growth can create an imbalance between inhibitory and stimulatory angiogenic molecules, resulting in endothelial cell proliferation and recruitment. Haematopoietic and EPC proliferation results in an increase in their circulating number, which, in response to tumour-derived chemokine secretion, recruits leukocytes to nascent primary and secondary tumour foci contributing to the neovasculature. This increased vascularity facilitates tumour growth and access to the circulation and is associated with a positive correlation between vascular density and tumour grade 159 . Angiogenesis, the formation of new vessels from pre-existing endothelial cells, is not the only mechanism of tumour neovascularization. Tumour vasculature can also arise by vasculogenesis; that is, de novo vessel formation by the recruitment, migration, proliferation and differentiation of bone marrow-derived EPCs 160 . Mobilized from the bone marrow by growth factors or chemotherapy 161 , EPCs become involved in tumour vasculogenesis 162 . Further, inhibiting EPC mobilization can slow or prevent tumour growth 163 , and several studies have shown that circulating EPC numbers correlate with clinical outcomes 164 . VEGFA is a major regulator that can affect EPC proliferation and differentiation, and it can attract EPCs (which is blocked by neutralizing VEGFA antibody) 91, 165 . Taken together, these studies indicate that tumour-secreted factors can induce the proliferation and differentiation, and support the survival, of EPCs and endothelial cells 166 . The extent of MDSC-derived tumour vasculature may depend on the tumour, as EPCs are found at high levels in mice bearing Lewis lung carcinomas, but are absent in mice bearing B16 melanomas, despite similar levels of microvasculature between these tumours 167 . In addition to directly contributing to the vasculature, myeloid progenitor cells also promote tumour growth. Admixing myeloid cells with tumour cells, under conditions that promote vascular leukocyte generation, results in larger and more highly vascularized tumours 168 . Both G-CSF and VEGFA mobilize EPCs into the peripheral circulation and promote angiogenesis 169 . 
. As EPCs can become part of the tumour vasculature 170 , their mobilization in response to tumour secretion of VEGFA, G-CSF or GM-CSF, contributes to tumour vascular formation. In contrast to tumour-bearing mice, non-tumour-bearing mice injected with G-CSF do not increase the levels of circulating EPCs, suggesting that additional tumour-associated cytokines are required, such as VEGFA, which can also mobilize EPCs from the bone marrow 169 . MDSC regulation of host defence. The tumour microenvironment, once established, can inhibit host immunity. Tumours are not passive targets for host immunity; rather, they can downregulate antitumour immune responses through multiple mechanisms, including tumour-secreted factors, as well as mechanisms that result from changes in tissue homeostasis. During tumour progression and immunotherapy, tumour cell populations may be selected with increased resistance to immunosurveillance and immunotherapy. In addition, variants arise that can interfere with multiple stages of immune cell development, differentiation, migration and cytotoxicity 158 . Thus, multiple aspects of antitumour immunity are subject to regulation by the tumour microenvironment 171 . Although there are multiple mechanisms supporting tumour escape from host immunity 172 , in recent years, MDSCs have been a focus primarily because they are ubiquitous and associated with disease progression and poor prognosis 173, 174 . Many studies that examined hosts with advanced tumour burden also reported reduced T cell frequency and function. The relationship between tumour burden and immunosuppression raises the question of whether tumour-induced immunosuppression is reversible by surgical removal of the primary tumour. Several studies have assessed immunosuppression after primary tumour resection in mice 13, 14, 28 , and varying effects on immunosuppression have been reported, including partial recovery of T cell function 13, 28 . VEGFA is an immunosuppressive cytokine that blocks normal myeloid cell differentiation, resulting in increased MDSC-mediated inhibition of T cell activity 46, 71, 175 . Thus, surgery may reverse immunosuppression in some cases, and this is associated with a reduction in immunosuppressive factors, thereby supporting immune recovery. However, immunosuppression may reoccur as metastatic lesions grow and inhibitory cytokine levels increase. Numerous reviews of the mechanisms associated with MDSC suppression of T cell function have been published in recent years with a focus on iNOS 176 , reactive oxygen species (ROS), ARG1 (REF. 177 ), cyclooxygenase 2 (COX2) and the potential upregulation of IL-10 as primary mechanisms. See any of the recent reviews on this subject for additional information 43, 73, 178 .
MDSCs: roles in cancer therapy
Numerous enzymes, growth factors and cytokines regulate the MDSC lifecycle, including their expansion, trafficking, differentiation and function
. Inhibitors of most of these regulatory mediators are identified in TABLE 1. These molecular inhibitors include a variety of drugs that target tyrosine kinases 67 , such as cGMP-specific 3ʹ,5ʹ-cyclic phosphodiesterase (PDE5A) 144 , peroxisome proliferator-activated receptor-γ (PPARγ) 179 , amino-bisphosphonates 180 and COX2 (REF. 181 ), in addition to the antibodies and molecular inhibitors of cytokines and chemokines discussed above. Indeed, several recent reviews have focused on this aspect of MDSC pathobiology 173 ; therefore, we briefly discuss the ability of MDSCs to inhibit responses to standard-of-care therapeutics below. For example, VEGFR2 (also known as FLK1 and KDR) tyrosine kinase inhibitors (TKIs) that target angiogenesis also partially inhibit the tumour growth stimulatory effects of G-CSF via MDSC proliferation, an observation that supports a role for VEGFA in tumour progression and evasion of host immunity. Clinically, administration of the TKI inhibitor sunitinib to patients with metastatic RCC significantly reduces MDSC numbers in the peripheral blood 67, 182 . MDSCs may also contribute to resistance to sunitinib therapy via secretion of the Bombina variagata peptide 8 homologue (BV8) 183 , potentially secondary to its upregulation by tumour-secreted G-CSF 19 . IL-8 also contributes to sunitinib resistance, as shown in an RCC xenograft model in which sunitinib-induced resistance was reversed by co-treatment with IL-8 antibodies 184 . As IL-8 has potent pro-angiogenic activity, its upregulation may induce pro-angiogenic pathways that allow tumours to escape the anti-angiogenic activity of sunitinib. Additional growth factors may also block therapeutic responses to inhibitors of VEGFA signalling by recruiting myeloid cells that promote angiogenesis and immune tolerance 185, 186 . In addition to factors that directly drive angiogenesis 187 , mediators may also function by recruiting myeloid cells to release angiogenic factors 188 . The bone marrow-derived myeloid cells that produce angiogenic factors and the accompanying escape from VEGFA inhibitors have also been observed in preclinical tumour models 95, 186 . Tumours resistant to inhibitors of VEGFA signalling can secrete cytokines that recruit myeloid cells that promote angiogenesis and immune tolerance 185 . In support of a role for chemokines in tumour progression, plasma levels of CXCL12 have been shown to correlate with metastasis in bevacizumab (monoclonal antibody to VEGFA)-treated patients with advanced rectal cancer 189 .
Concluding remarks
In recent years, there has been a heightened interest in MDSCs and their biological function in tumour pathobiology. As this Timeline article emphasizes, their contribution to tumour pathological processes goes far beyond immune suppression. MDSCs are a heterogeneous population of immature haematopoietic cells that have a role in immune tolerance, tumour progression and metastasis. Tumour progression is associated with increased numbers of these iMCs in the primary tumour microenvironment and circulation, which in turn is associated with a poor prognosis, supporting a role in metastasis. Recently, the controversy regarding the phenotype of human MDSCs has been resolved, with agreement concerning which subset or subsets should be monitored; that is, LIN 
